Short abstract
See related letter
To the Authors:
We thank Dr Akinosoglou and Dr Gogos for their valuable comments regarding our recent report on real‐world experience in the use of tocilizumab for treatment of coronavirus disease 2019 (COVID‐19) with hyperinflammatory state. 1 As they state, data on the potential benefit of treatment with interleukin‐6 receptor antagonists (IL‐6RA) in COVID‐19 remains inconsistent and they highlight potential concerns for adverse outcomes arising from blockade of IL‐6 receptor in those who are critically ill. However, observational studies demonstrate favourable outcomes regarding mortality and risk of proceeding to endotracheal intubation when IL‐6RA are used in a pre‐critical (pre‐intensive care unit (ICU)) setting, such as that described in our report, before the onset of severe respiratory failure. 2 Apart from optimal timing of drug administration, there also remains uncertainty regarding the optimal dosing of tocilizumab in this clinical setting. It has been suggested that some individuals might need higher or repeated doses of tocilizumab, due to persistently high levels of IL‐6 post‐treatment, which have been associated with worse clinical outcomes in some reports. 3
While the potential risk of bacterial infections represents a concern, a recently published rapid review and meta‐analysis including 28 studies showed that bacterial co‐infections and superinfections were reported in only 3.5% and 15.5% of patients with COVID‐19, respectively. 4 However, more than 70% of patients were treated with antibiotics, mostly empirically, which raises the concern that patients with COVID‐19 might receive unnecessary antibiotic treatment. On the other hand, the risk of bacterial infection may be higher in the ICU setting, where more frequent use of vascular and other indwelling devices represent a risk for bloodstream infections (BSI), which are also often reported in patients with COVID‐19. 5 Moreover, the use of anti‐inflammatory agents in the ICU setting, including tocilizumab, was associated with a higher risk of developing BSI, especially when used in combination with methylprednisolone. Considering the lack of convincing evidence on the clinical improvement of critically ill patients treated with IL‐6RA, the risks might outweigh the benefits in the critical setting. 2
Hence, optimal dosing and timing of such agents is essential and likely the administration in the pre‐ICU setting, prior to the establishment of end organ damage or acute respiratory distress syndrome (ARDS), may be of most benefit. To address these questions, our group has designed a phase 2, open‐label, two‐stage, multi‐centre, randomized trial comparing different doses of single‐dose administration of tocilizumab in adults with severe, non‐critical, COVID‐19 with evidence of hyperinflammatory state. 6 This study is limited to patients in a pre‐ICU setting, with specific exclusion criteria (such as history of immunosuppression, active malignancies, diverticulitis or intestinal perforation). In the first stage, standard of care (SOC) will be compared to SOC plus a single infusion of tocilizumab (8 mg/kg). (Fig. 1). On the basis of the findings from stage 1, the study will progress to stage 2, where patients will be randomized to a single dose of either standard dose (8 mg/kg) or a lower dose (4 mg/kg) of tocilizumab plus SOC. This and other ongoing trials on the use of IL‐6RA in patients with COVID‐19 will hopefully produce the much needed, high‐quality evidence on the efficacy and safety of treatment with immune modulatory agents in patients with severe COVID‐19.
Figure 1.
Clinical trial plan. Brief description of patient population (top left). Description of the two stages of the clinical trial (stage 1 and stage 2), with definition of the two study arms for each stage.
Acknowledgements
We would like to acknowledge all the authors who contributed to our original paper: Dr Eoin R. Feeney, Dr Marcus W. Butler, Dr Cathal O'Broin, Dr Silke Ryan, Dr Lorraine O'Neill, Dr David J. Murphy, Professor Charles G. Gallagher, Professor Edward F. McKone, Dr Sarmad Waqas, Dr Aoife Cotter, Professor Peter Doran and Professor Michael P. Keane. We would also like to thank all the patients who gave their consent to participate in the study, and all the staff members who were involved in the care of patients with COVID‐19 in St Vincent's University Hospital.
The All Ireland Infectious Diseases Cohort Study Collaborators: Professor Paddy Mallon, Dr Marcus Butler, Dr Aoife Cotter, Professor Paul Cotter, Professor Garry Courtney, Dr Fiona Crispie, Dr Eoghan de Barra, Professor Joe Eustace, Dr Eoin Feeney, Professor Sean Gaine, Professor Charles Gallagher, Dr Patrick Gavin, Professor Colin Hill, Dr Christine Kelly, Dr Barry Kevane, Professor Jack Lambert, Dr Justin Low, Dr Cormac McCarthy, Professor Samuel McConkey, Dr Brian McCullagh, Dr Padraig McGettrick, Dr Tara McGinty, Dr Bairbre McNicholas, Dr Eavan Muldoon, Professor Fionnuala Ní Áinle, Dr Cathal Ó Brion, Dr Dermot O'Callaghan, Dr Sarah O'Connell, Professor James O'Donnell, Professor Paul O'Toole, Dr Silke Ryan, Dr Corinna Sadlier, Dr Stefano Savinelli, Professor Gerard Sheehan, Dr Willard Tinago, Dr Bryan Whelan, Dr Obada Yousif, Professor Peter Doran (https://www.ucd.ie/medicine/cephr/allirelandinfectiousdiseasescohortstudy/).
Savinelli S, McCarthy C, Mallon PW, All Ireland Infectious Diseases (AIID) Cohort Collaborators:. Reply. Respirology. 2020;25:1210–1211. 10.1111/resp.13940
REFERENCES
- 1. McCarthy C, Savinelli S, Feeney ER, Butler MW, O'Broin C, Ryan S, O'Neill L, Murphy DJ, Gallagher CG, McKone EF et al. Tocilizumab therapy in individuals with COVID‐19 infection and hyperinflammatory state. Respirology 2020. 10.1111/resp.13912. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Sinha P, Mostaghim A, Bielick CG, McLaughlin A, Hamer DH, Wetzler L, Bhadelia N, Fagan M, Linas BP, Assoumou SA et al. Early administration of interleukin‐6 inhibitors for patients with severe Covid‐19 disease is associated with decreased intubation, reduced mortality, and increased discharge. Int. J. Infect. Dis. 2020; 99: 28–33. 10.1016/j.ijid.2020.07.023. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Quartuccio L, Sonaglia A, Pecori D, Peghin M, Fabris M, Tascini C, De Vita S. Higher levels of IL‐6 early after tocilizumab distinguish survivors from nonsurvivors in COVID‐19 pneumonia: a possible indication for deeper targeting of IL‐6. J. Med. Virol. 2020. 10.1002/jmv.26149. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, Soucy JR, Daneman N. Bacterial co‐infection and secondary infection in patients with COVID‐19: a living rapid review and meta‐analysis. Clin. Microbiol. Infect. 2020. 10.1016/j.cmi.2020.07.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Giacobbe DR, Battaglini D, Ball L, Brunetti I, Bruzzone B, Codda G, Crea F, De Maria A, Dentone C, Di Biagio A et al. Bloodstream infections in critically ill patients with COVID‐19. Eur. J. Clin. Invest. 2020: 10.1111/eci.13319. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Cotter A, Wallace D, McCarthy C, Feeney E, O'Neill L, Stack J, McCarthy G, Hussain R, Alvarez Barco E, Doran P et al. The COVIRL002 trial‐tocilizumab for management of severe, non‐critical COVID‐19 infection: a structured summary of a study protocol for a randomised controlled trial. Trials 2020. 10.1186/s13063-020-04680-w. [DOI] [PMC free article] [PubMed] [Google Scholar]